Tigilanol tiglate, branded as STELFONTA®, is approved and marketed as a veterinary pharmaceutical for treatment of non-metastatic, canine mast cell tumours1,2  in the European Union, Switzerland, United Kingdom, Australia and United States of America. (this link will take you to a product site that contains information that may not comply with the Australian regulatory requirements.)

STELFONTA® is marketed and distributed in these jurisdictions through a partnership with Virbac, a global animal health company.


  1. STELFONTA® (tigilanol tiglate injection) packaging insert (2020) 
  2. European Medicines Agency. (2020).STELFONTA®.